UCLA-tested pancreatic cancer drug doubles survival
- Posted on June 16, 2026
- By Bing News
- 0 Views
- 1 min read
UCLA-tested pancreatic cancer drug doubles survival
A daily pill doubled patients’ survival in metastatic pancreatic cancer treatment by blocking one of the primary drivers of the tumor, researchers from the University of California, Los Angeles reported. Patients who received daraxonrasib, an investigational, first-in-class oral drug designed to block one of the primary drivers of pancreatic cancer, lived a median of 13.2 months compared with ...
